In mid to late 2025, around 12.4% of US adults reported taking a GLP-1 medicine specifically for weight loss, up from 5.8% in February 2024, according to Gallup survey data of more than 15,000 adults
These factors can negatively impact the consumers from price-sensitive regions where the disposable income is low, further widening health disparities
Sales of a new class of weight loss drugs known as GLP-1s have transformed Eli Lilly $LLY and Novo Nordisk into the most valuable pharmaceutical companies in the world
Symptoms like hair loss, fatigue, flaky skin, or bruising, muscle weakness, poor wound healing may indicate insufficiency (Mozafariun et al 2025)
Its effects in vivo were therefore tested during insulin-induced hypoglycaemia (glucose lowered to ~3 mmol/l)
This brings me to my last point